- A 52-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis
To compare the efficacy of relamorelin with that of placebo in participants with DG with respect to a composite of the following core signs and symptoms of DG:
Nausea
Abdominal Pain
Postprandial fullness
Bloating
- 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis
To compare the efficacy of relamorelin with placebo in participants with Diabetic Gastroparesis with respect to a composite of the following core signs and symptoms of: *Nausea *Abdominal pain *Postprandial fullness *Bloating
- A 46-week, Double-blind, Placebo-controlled, Phase 3 Study with a 6-week
Randomized-withdrawal Period to Evaluate the Safety and Efficacy of Relamorelin in
Patients with Diabetic Gastroparesis
Extension study for RLM-MD-02 participants. To compare the efficacy of relamorelin with placebo in participants after 12 weeks of treatment. Total of 24 weeks (12 weeks from RLM-MD-02 study and 12 weeks from this study)